LINC00881: A Drug Target / Disease Biomarker (G100498859)

Target Name: LINC00881

NCBI ID: G100498859

LINC00881

Other Name(s): Long intergenic non-protein coding RNA 881 | long intergenic non-protein coding RNA 881

LINC00881: A Drug Target / Disease Biomarker

LINC00881 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the most promising aspects of LINC00881 is its potential as a drug target. LINC00881 has been shown to play a role in a variety of cellular processes that are important for human health, including cell division, migration, and survival. It has also been shown to interact with a number of different proteins, including TGF-β1, which is a well-known regulator of cell growth and differentiation.

In addition to its potential as a drug target, LINC00881 has also been shown to be a potential biomarker for a number of diseases. For example, studies have shown that LINC00881 is downregulated in a variety of cancer tissues, and that high levels of LINC00881 are associated with poor prognosis in patients with various types of cancer. Additionally, LINC00881 has been shown to be involved in the development and progression of neurodegenerative diseases, and may be a useful biomarker for these conditions as well.

Overall, LINC00881 is a protein that has the potential to be a drug target or biomarker, and further research is needed to fully understand its role in human health and disease.

Protein Name: Long Intergenic Non-protein Coding RNA 881

The "LINC00881 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00881 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets